Eris Lifesciences Limited

BSE:540596 Stock Report

Market Cap: ₹186.0b

Eris Lifesciences Valuation

Is 540596 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 540596 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 540596 (₹1376.15) is trading above our estimate of fair value (₹1108.31)

Significantly Below Fair Value: 540596 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 540596?

Key metric: As 540596 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 540596. This is calculated by dividing 540596's market cap by their current earnings.
What is 540596's PE Ratio?
PE Ratio53.7x
Earnings₹3.48b
Market Cap₹186.04b

Price to Earnings Ratio vs Peers

How does 540596's PE Ratio compare to its peers?

The above table shows the PE ratio for 540596 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average42.7x
524558 Neuland Laboratories
68.4x33.9%₹189.8b
MARKSANS Marksans Pharma
40.3x22.3%₹140.1b
524742 Caplin Point Laboratories
30.3x13.6%₹147.7b
APLLTD Alembic Pharmaceuticals
31.7x21.5%₹204.0b
540596 Eris Lifesciences
53.7x30.7%₹186.0b

Price-To-Earnings vs Peers: 540596 is expensive based on its Price-To-Earnings Ratio (53.7x) compared to the peer average (42.7x).

Price to Earnings Ratio vs Industry

How does 540596's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$71.82m
524652 Ind-Swift
2xn/aUS$13.29m
No more companies available in this PE range
540596 53.7xIndustry Avg. 31.6xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 540596 is expensive based on its Price-To-Earnings Ratio (53.7x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 540596's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

540596 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.7x
Fair PE Ratio47.7x

Price-To-Earnings vs Fair Ratio: 540596 is expensive based on its Price-To-Earnings Ratio (53.7x) compared to the estimated Fair Price-To-Earnings Ratio (47.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 540596 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,376.15
₹1,503.11
+9.2%
9.0%₹1,680.00₹1,230.00n/a9
Nov ’25₹1,347.70
₹1,503.11
+11.5%
9.0%₹1,680.00₹1,230.00n/a9
Oct ’25₹1,323.00
₹1,334.44
+0.9%
14.8%₹1,680.00₹1,075.00n/a9
Sep ’25₹1,389.90
₹1,243.33
-10.5%
11.0%₹1,580.00₹1,075.00n/a9
Aug ’25₹1,119.05
₹1,110.56
-0.8%
7.6%₹1,270.00₹980.00n/a9
Jul ’25₹1,050.25
₹1,091.67
+3.9%
8.2%₹1,270.00₹950.00n/a9
Jun ’25₹916.20
₹1,091.67
+19.2%
8.2%₹1,270.00₹950.00n/a9
May ’25₹891.60
₹1,079.44
+21.1%
9.0%₹1,230.00₹930.00n/a9
Apr ’25₹850.05
₹1,079.44
+27.0%
9.0%₹1,230.00₹930.00n/a9
Mar ’25₹885.70
₹1,075.63
+21.4%
8.4%₹1,230.00₹950.00n/a8
Feb ’25₹905.70
₹1,032.78
+14.0%
10.2%₹1,230.00₹900.00n/a9
Jan ’25₹905.15
₹1,013.33
+12.0%
8.9%₹1,170.00₹890.00n/a9
Dec ’24₹924.40
₹993.89
+7.5%
7.1%₹1,110.00₹890.00n/a9
Nov ’24₹864.30
₹970.00
+12.2%
6.7%₹1,110.00₹890.00₹1,347.709
Oct ’24₹877.05
₹916.50
+4.5%
7.7%₹1,040.00₹790.00₹1,323.0010
Sep ’24₹806.95
₹902.78
+11.9%
6.7%₹995.00₹790.00₹1,389.909
Aug ’24₹797.00
₹799.44
+0.3%
6.4%₹920.00₹735.00₹1,119.059
Jul ’24₹697.85
₹785.00
+12.5%
7.5%₹920.00₹720.00₹1,050.259
Jun ’24₹639.75
₹785.00
+22.7%
7.5%₹920.00₹720.00₹916.209
May ’24₹630.10
₹791.11
+25.6%
10.7%₹1,000.00₹690.00₹891.609
Apr ’24₹572.05
₹805.56
+40.8%
9.6%₹1,000.00₹710.00₹850.059
Mar ’24₹630.90
₹827.22
+31.1%
6.9%₹975.00₹770.00₹885.709
Feb ’24₹613.60
₹827.22
+34.8%
6.9%₹975.00₹770.00₹905.709
Jan ’24₹645.50
₹869.44
+34.7%
6.7%₹975.00₹800.00₹905.159
Dec ’23₹670.25
₹869.44
+29.7%
6.7%₹975.00₹800.00₹924.409
Nov ’23₹724.50
₹875.50
+20.8%
6.6%₹975.00₹800.00₹864.3010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%

Bal Pharma

₹2.2b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹137.15

7D

13.8%

1Y

30.6%

Caplin Point Laboratories

₹147.7b

Engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India.

CAPLIPOINT

₹1,963.75

7D

0.6%

1Y

59.7%